Intra-abdominal sepsis

Current Opinion in Infectious Diseases

Volumn 9, Issue 5, 1996, Pages 353-358

  Foitzik, Thomas ^a   Runkel, Norbert ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFOTAXIME; CYTOKINE; ENTEROTOXIN; IMIPENEM; MEROPENEM; METRONIDAZOLE;

ABDOMINAL DRAINAGE; ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; DIGESTIVE SYSTEM PERFORATION; ENTEROBACTERIACEAE; HUMAN; IMMUNE RESPONSE; INTENSIVE CARE; LAPAROTOMY; LAVAGE; MORTALITY; MULTIPLE ORGAN FAILURE; SEPSIS; SHORT SURVEY;

EID: 0029797130     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199610000-00012     Document Type: Short Survey

References (90)

1. McClean KL, Sheehan GJ, Harding GKM: Intra-abdominal infection: A review. Clin Infect Dis 1994, 19:100-116.
2. Centers of Disease Control: Increase in national hospital discharge survey rates for septicemia - United States 1979-1987. JAMA 1990, 263:937-938.
3. Brun-Buisson C, Doyon F, Cartel J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B: Incidence, risk factors, and outcome of severe sepsis and septic shock. JAMA 1995, 274:968-974.
4. Bartlett JG: Intra-abdominal Sepsis. Med Clin North Am 1995, 79:599-617. An excellent review focusing on the natural history and microbiology of intra-abdominal sepsis as well as on diagnostic studies, antibiotic treatment and percutaneous catheter drainage.
5. Horwitz JR, Lally KP, Cheu HW, Vazquez WD, Grosfeld JL, Ziegler MM: Complications after surgical intervention for necrotizing enterocolitis: a multicenter review. J Pediatr Surg 1995, 30:994-999.
6. Peer A, Witz E, Manor H, Strauss S: Intrahepatic abscess due to gallbladder perforation. Abdom Imaging 1995, 20:452-455.
7. Bhuva M, Ganger O, Jensen D: Spontaneous bacterial peritonitis: an update on evaluation, management and prevention. Am J Med 1994, 97:169-175.
8. Fombuena-Moreno M, Calvo-Catala J, Gonzalez-Cruz-Cervellera MI, Hortelano-Martinez E, Herrera-Ballester A, Gomez-Ballestin S: Splenic abscess following gynecologic infection with complete response to antibiotic treatment. Ann Med Interna 1995, 12:340-342.
9. Foitzik T, Quentmeier A, Klar E, Buhr HJ, Herfarth C: Pneumoretroperitoneum in a patient with acute biliary pancreatitis. Eur J Surg 1996, 162:507-509.
10. Fee MJ, Oo MM, Gabayan AE, Radin DR, Barnes PF: Abdominal tuberculosis in patients infected with the human immunodeficiency virus. Clin Infect Dis 1995, 20:938-944.
11. Eddy VA, Snell JE, Morris JA Jr: Analysis of complications and long-term outcome of trauma patients with needle catheter jejunostomy. Am Surg 1996, 62:40-44.
12. Shocket E: Abdominal abscess from gallstones spilled at laparoscopic cholecystectomy: case report and review of the literature. Surg Endosc 1995, 9:344-347. This article, documenting 15 cases of intra-abdominal abscess formation caused by spilled gallstones, alerts us to an uncommon, yet serious complication of laparoscopic cholecyslectomy.
13. Dunn DL, Simmons RL: Fibrin in peritonitis. III. The mechanism of bacterial trapping by polymerizing fibrin. Surgery 1982, 92:513-519.
14. Dunn DL, Barke RA, Condie RM, Lee JT, Humphrey EW, Simmons RL: Mechanisms of the adjuvant effect of hemoglobin in experimental peritonitis. VII. Hemoglobin does not inhibit clearance of E. coli from the peritoneal cavity. Surgery 1983, 94:487-495.
15. Dunn DL, Barke RA, Ahrenholz DH, Humphrey EW, Simmons RL: The adjuvant effect of peritoneal fluid in experimental peritonitis: mechanisms and clinical implications. Ann Surg 1984, 199:37-43.
16. Schlag G, Redl H: Mediators of injury and inflammation. World J Surg 1996, 20:406-410. This article explains the mediator cascades and their complex interactions in a clear, easy-to-understand manner.
17. Guirano X, Lowry SF: Biological control of injury and inflammation: Much more than too little or too late. World J Surg 1996, 20:437-446. This article provides insight into the mechanisms of cytokine release and counter-regulation, hypothesizing that it is a sustained imbalance between pro-inflammatory and counter-regulatory influences that predicts the course and outcome of sepsis.
18. Goris RJA: MODS/SIRS: result of an overwhelming inflammatory response? World J Surg 1996, 20:418-421. This study discusses the role of an overwhelming and uncontrolled inflammatory process in producing SIRS, MODS and multiple organ failure.
19. Faist E, Schinkel C, Zimmer S: Update on the mechanisms of immune suppression and injury and immune modulation. World J Surg 1996, 20:454-459. This article gives an update on immunosuppression and insight into potential strategies for immune modulation.
20. Bone RC: Toward a theory regarding the pathogenesis of the septic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 1996, 24:163-172.
21. Neugebauer E, Dimmeler S, Troidl H: Mediator systems and sepsis [in German]. Chirurg 1995, 66:2-10.
22. Stadler J, Heidecke CD, Bartels H, Holzmann B, Wagner H, Siewert JA: Immunsupression und Sepsis. Chirurg 1995, 66:11-17.
23. Livingston DH, Mosenthal AC, Deitch EA: Sepsis and multiorgan dysfunction syndrome: a clinical-mechanistic overview. New Horizons 1995, 3:257-266.
24. Schein M, Wittmann DH, Holzheimer R, Condon RE: Hypothesis: Compartmentalization of cytokines in intra-abdominal infection. Surgery 1996, 119:694-700. Many patients with intra-abdominal infections die of uncontrolled sepsis despite clearance of the peritoneal cavity from infective concentrations of bacteria. The authors provide evidence that the relevant cytokine-mediated inflammatory process is compartmentalized in the peritoneal cavity, and suggest that novel therapeutic strategies should be directed against this local response.
25. Nieuwenhuijzen GAP, Deitch EA, Goris RJA: Infection, the gut and the development of the multiple organ dysfunction syndrome. Eur J Surg 1996, 162:259-273. This article describes failure of the gut barrier and provides further evidence for the hypothesis that gut lumen contents contributes to autointoxication, impairment of immune defence, tissue destruction and multiple organ failure in critically ill patients.
26. Swank GM, Deitch EA: Role of the gut in multiple organ failure. Bacterial translocation and permeability changes. World J Surg 1996, 20:411-417.
27. Andersson R, Wang X, Ihse I: The influence of abdominal sepsis on acute pancreatitis in rats: a study on mortality, permeability, arterial pressure and intestinal blood flow. Pancreas 1995, 11:365-373.
28. Meyer TA, Wang Jingjing W, Tiao GM, Ogle CK, Fischer JE, Haselgren PO: Sepsis and endotoxemia stimulate intestinal interleukin-6 production. Surgery 1995, 118:336-342.
29. Ahrenholz DH, Simmons RL: Peritonitis and other intra-abdominal infections. In Surgical infectious diseases (2nd edn) Edited by Howard RJ, Simmons RL. Norwalk; Appleton and Lange; 1988:605-646.
30. Nord CE: Incidence and significance of intraperitoneal aerobic and anaerobic bacteria. Clin Ther 1990, 12:9-20.
31. Walker AP, Krepel CJ, Gohr CM, Edmiston CE: Microflora of abdominal sepsis by locus of infection. J Clin Microbiol 1994, 32:557-558.
32. Grant SW, Hopkins J, Wilson SE: Operative site bacteriology as an indicator of prognostic infectious complications in elective colorectal surgery. Am Surg 1995, 61:856-861.
33. Burnett RJ, Haverstock DC, Dellinger EP, Reinhart HH, Bohnen JM, Rotstein OD, Vogel SB, Solomkin JS: Definition of the role of enterococcus in intra-abdominal infections: analysis of a prospective randomized trial. Surgery 1995, 118:716-723.
34. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P: Clinical significance of candida isolated from peritoneum in surgical patients. Lancet 1989, ii:1437-1440.
35. Dean DA, Burchard KW: Fungal infection in surgical patients. Am J Surg 1996, 171:374-381.
36. Bone RC, Sibbald WJ, Sprung CL: The ACCP-SCCM consensus conference on sepsis and organ failure [Editorial]. Chest 1992, 101:1481-1483.
37. Nyström PO: Sepsis: current definitions and stratification systems. In Modulation of the inflammatory response in severe sepsis. Edited by Tellado JM, Forse RA, Solomkin JE. Basel: Karger; 1995: 1-7. [Prog Surg, 20] .
38. Nathans AB, Marshall JC: Sepsis, SIRS, and MODS: what's in a name. World J Surg 1996, 20:386-391.
39. Fry DE: Noninvasive imaging tests in the diagnosis and treatment of intra-abdominal abcesses in the postoperative patient. Surg Clin North Am 1994, 74:693-709.
40. Uhl W, Beger HG, Hoffmann G, Hanisch E, Schild A, Waydhas C, Entholzner E, Müller K, Kellermann W, Vogeser M et al.: A multicenter study of phospholipase A2 in patients in intensive care units. J Am Coll Surg 1995, 180:323-331.
41. H2 lymphocyte response during intra-abdominal abcess formation, suggesting that serum lysozyme and IL-10 may serve as reliable and relatively inexpensive tools for the diagnosis of intra-abdominal abscesses.
42. Reith HB, Lehmkuhl P, Beier W, Högy B: Procalcitonin. Ein prognostischer Infektionsparameter bei der Peritonitis. Chir Gastroenterol 1995, 11(suppl 2):47-50.
43. Gramm HJ, Dollinger P, Beier W: Procalcitonin. Ein neuer Marker der inflammatorischen Wirtsantwort Longitudinalstudien bei Patienten. Chir Gastroenterol 1995, 11(suppl 2):51-54.
44. Haupt W, Zirngibl H, Klein P, Hohenberger W: Monocytenfunction. Aktivierung und postoperative Komplikationen. Chir Gastroenterol 1995, 11(suppl 2):15-19.
45. Okita M: Studies of liver macrophage function in intra-abdominal infection after partial hepatectomy in the rat model. Nippon Geka Gakkai Zasshi 1995, 96:685-694.
46. Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah K, Müller JM, Kox WJ, Döcke A: HLA-DR-Expression auf Monocyten bei Peritonitis und Sepsis. Möglichkeiten eines therapeutischen Ansatzes. Chir Gastroenteol 1995, 11(suppl 2):34-41. The authors discuss the failure of blocking the production or action of tumour necrosis factor and IL-1 in clinical sepsis trials concluding that anti-inflammatory therapy may only be successful in the initial hyperinflammatory phase of sepsis. They suggest exact immune analysis for a better stratification of patients for future studies.
47. Billing A, Mialkowskyi O, Schildberg FW: Prognose des Multiorganversagens. Chir Gastroenterol 1995, 11(suppl 2):20-25.
48. Bartels H, Barthlen W, Stadler J, Siewert JR: Therapieaspekte bei septischen Abdominalerkrankungen. Chir Gastroenterol 1995, 11(suppl 2):9-14.
49. Anderson ID, Fearon KCH, Grant IS: Laparotomy for abdominal sepsis in the critically ill. Br J Surg 1996, 83:535-539. Based on their experience with 125 patients with severe intra-abdominal sepsis, the authors discuss alternative surgical strategies in the treatment of these critically ill patients, concluding that aggressive surgical regimens may offer survival advantages.
50. Levison MA: Percutaneous versus open operative drainage of intra-abdominal abcessess. Infect Dis Clin North Am 1992, 6:525-544.
51. Shuler FW, Newmann CN, Angood PB, Tucker JG, Lucas GW: Nonoperative management for intra-abdominal abcesses. Am Surg 1996, 62:218-222. The findings of this study suggest a limited application of percutaneous catheter drainage of intra-abdominal abcesses in patients with colonic diverticular disease or colon cancer, and abscesses localized to the left lower quadrant.
52. McLaughlan GJ, Anderson ID, Grant IS, Fearon KCH: Outcome of patients with abdominal sepsis treated in an intensive care unit. Br J Surg 1995, 82:524-529.
53. Brandt CP, McHenry CR, Jacobs DG, Piotrowski JJ, Priebe PP: Polypropylene mesh closure after emergency laparotomy. Morbidity and outcome. Surgery 1995, 118:736-741.
54. Cunha BA: Antibiotic treatment of sepsis. Med Clin North Am 1995, 79:551-558. An excellent review on all major aspects of the antibiotic treatment of sepsis.
55. Rovers JP, Ilersich AL, Einarson TR: Meta-analysis of parenteral clindamycin dosing regimens. Ann Pharmacother 1995, 29:852-858.
56. Dipiro JT: Considerations for therapy of mixed infections. Focus on intra-abdominal infection. Pharmacotherapy 1995, 15:15-21.
57. Shyr YM, Lui WY, Su CH, Wang LS, Liu CY: Piperacillin/tazobactam in comparison with clindamycin plus gentamycin in the treatment of intra-abdominal infections. Chung Hua I Hsueh Tsa Chih Taipei 1995, 56:102-108.
58. Pitkin D, Sheikh W, Wilson S, Hemsell D, Nichols R, Nadler H, Dowzicky M: Comparison of the activity of meropenem with that of other agents in the treatment of intra-abdominal, obstetric/gynecologic and skin and soft tissue infections. Clin Infect Dis 1995, 20(suppl 2):372-375.
59. Condon RE, Walker AP, Sirinek KR, White PW, Fabian TC, Nichols RL, Wilson SE: Meropenem versus tobramycin plus clindamycin for treatment of intra-abdominal infections. Results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995, 21:544-550.
60. Sullivan MC, Nightingale CH, Quintiliani R, Sweeney KR: Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam. Pharmacotherapy 1995, 15:479-486.
61. Aprahamian C, Schein M, Wittmann D: Cefotaxime and metronidazole in severe abdominal infection. Diagn Microbiol Infect Dis 1995, 22:183-188.
62. Solomkin JS, Reinhart HH, Dellinger EP, Bohnen JM, Rotstein OD, Vogel SB, Simms HH, Hill CS, Bjornson HS, Haverstock DC et al. and the Intra-abdominal Infection Study Group: Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/clistatin for intra-abdominal infections. Ann Surg 1996, 223:303-315 The latest report of the Intra-abdominal Infection Study Group demonstrating statistical equivalence between intravenous ciprofloxacin/metronidazole and intravenous imipenem for the treatment of intra-abdominal infections and that conversion to oral therapy with ciprofloxacin/metronidazole is as effective as continued intravenous therapy in patients able to tolerate oral feeding.
63. Sainio V, Kemppainen E, Puolakkainen P, Taavitsainen M, Kivisaari L, Valtonen V, Haapiainen T, Schröder T, Kivilaasko E: Early antibiotic treatment in acute necrotising pancreatitis. Lancet 1995, 346:663-667.
64. Mithöfer K, Fernandez-del Castillo C, Ferraro MJ, Lewandrowski K, Rattner DW, Warshaw AL: Antibiotic treatment improves survival in experimental acute necrotizing pancreatitis. Gastroenterology 1996, 110:232-240.
65. Luiten EJ, Hop WCJ, Lange JF, Bruining HA: Controlled clinical trial of selective decontamination for the treatment of severe acute pancreatitis. Ann Surg 1995, 222:57-65 This controlled clinical trial demonstrates that reduction of Gram-negative colonization of the digestive tract, and preventing subsequent pancreatic infection significantly reduces morbidity and mortality in patients with severe acute pancreatitis.
66. Foitzik T, Fernandez-del Castillo C, Ferraro MJ, Mithöfer K, Rattner DW, Warshaw AL: Pathogenesis and prevention of early pancreatic infection in experimental acute pancreatitis. Ann Surg 1995, 222:179-185.
67. Vincent JL: Prevention and therapy of multiorgan failure. World J Surg 1996, 20:465-470. This article provides practical recommendations for the resuscitation and support of patients with sepsis to prevent MODS and support patients if they develop multiple organ failure.
68. Baue AE, Durham RM, Mazuski JE: Clinical trials of new and novel therapeutic agents. World J Surg 1996, 20:493-498. This article reviews advances in circulatory, pulmonary and gut support, advises on monitoring and discusses indications for early operations in septic patients. Furthermore, new therapeutic agents such as growth factors, glucan, ketaconazole and antithrombin III are described.
69. Bengmark S, Gianotti L: Nutritional support to prevent and treat multiple organ failure. World J Surg 1996, 20:474-481 This article addresses nutritional support to prevent and treat multiple organ failure. Special attention is given to the importance of salvia, gastric acid, nutrients for the mucosa including glutamine, arginine, fermented oats and lactobacillus.
70. Shabert J, Ehrlich N: The ultimate nutrient glutamine. New York: Avery Publishing Group: 1994.
71. Foitzik T, Stufler M, Hotz HG, Klinnert J, Wagner J, Warshaw AL, Schulzke JD, Fromm M, Buhr HJ: Glutamine stabilizes intestinal permeability and reduces pancreatic infection in acute experimental pancreatitis [Abstract]. Gastroenterology 1996, 110(suppl):A1385.
72. Christmann JW, Holden EP, Blackwell TS: Strategies for blocking the systemic effects of cytokines in the sepsis syndrome. Crit Care Med 1995, 23:955-963. This article reviews and evaluates recent animal and human data regarding strategies to intervene in the pathogenesis of the sepsis syndrome by specifically blocking the action of single cytokines, namely tumour necrosis factor, IL-1, IL-6 and IL-8.
73. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Math B, Lansang MAD, Fisher CJ: Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995, 23:1430-1439.
74. Curley P, Nestor M, Collins K, Saporoschetz I, Mendez M, Mannick JA, Rodrick ML: Decreased interleukin-2 production in murine acute pancreatitis: potential for immunomodulation. Gastroenterology 1996, 110:583-588.
75. Hughes CB, Gaber LW, Mohey EL-Din AB, Grewal HP, Koth M, Mann L, Gaber AO: Inhibition of TNF improves survival in an experimental model of acute pancreatitis. Am Surg 1996, 1:8-13. The animal data presented provide strong evidence that tumour necrosis factor-χ is a major contributor to the morbidity and mortality from acute pancreatitis and that therapy with anti-tumour necrosis factor-χ polyclonal antibodies can ameloriate disease severity.
76. Abraham E, Wunderdink R, Silverman H, Perl TM, Nasraways S, Levy H, Bone R, Wenzel RP, Balk P, Allred R: Efficacy and safety of monoclonal antibody to human TNF in patients with sepsis syndrome. JAMA 1995, 273:934-941.
77. Windsor ACJ, Klava A, Somers SS, Guillou PJ, Reynolds JV: Manipulation of local and systemic host defense in the prevention of perioperative sepsis. Br J Surg 1995, 82:1460-1467.
78. Fisher CJ, Zheng Y: Potential strategies for inflammatory mediator manipulation:retrospect and prospect. World J Surg 1996, 20:447-453. This article reviews trials involving novel strategies of inflammatory mediator control in sepsis, concluding that so far they have failed to demonstrate clinical efficacy despite overwhelming animal data suggesting potential therapeutic benefit. The authors point out potential mistakes and the need for a more careful selection and stratification of patients, and standardization of therapy for future studies.
79. Hirasawa H, Sugai T, Ohtake Y, Oda S, Matsuda K, Kitamura N: Blood purification for prevention and treatment of multiple organ failure. World J Surg 1996; 20:482-486 Data presented within this article provide evidence for the improvement in oxygen consumption in patients with sepsis, associated with a decrease in certain cytokines after the cleansing of blood by various filtration and dialysis techniques.
80. Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D: Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Kidney Intern 1995, 48:1563-1570.
81. Reith HB, Debus S, Thiede A: Immunparalyse und Sepsis - Therapeutische Möglichkeiten. Chir Gastroenterol 1995, 11(suppl 2):5-8.
82. Richter A, Nebe T, Fiedler F, Trede M: Immunmonitoring bei akuter Pankreatitis. Chir Gastroenterol 1995, 11(suppl 2):26-33.
83. Barriere SL, Lowry SF: An overview of mortality risk prediction in sepsis. Crit Care Med 1995, 23:376-393.
84. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
85. Hadley S, Samore MH, Lewis WD, Jenkins RL, Karchmer AW, Hammer SM: Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995, 59:851-859.
86. Zimmermann JE, Knaus WA, Sun X, Wagner DP: Severity stratification and outcome for multisystem failure and dysfunction. World J Surg 1996, 20:401-405.
87. Pittet D, Thievent B, Wenzel RP, Li N, Auckenthaler R, Suter PM: Bedside prediction of mortality from bacteremic sepsis. Am J Respir Crit Care Med 1996, 153:684-693.
88. Pacelli F, Goglietto GB, Alftieri S, Piccioni E, Sgadari A, Gut D, Crucitti F: Prognosis of intra-abdominal infections. Arch Surg 1996, 131:641-645. This multivariate analysis of 604 patients with intra-abdominal infections shows a dominance of host-related factors over the type and source of infection on prognosis. Both, the APACHE-II Score and the Mannheim Peritonitis Index (as well as hypocholesterolaemia, and preoperative organ impairment) were independent predictors of death.
89. Hurley JC: Reappraisal with meta-analysis of bacteremia, endotoxemia and mortality in gram negative sepsis. J Clin Microbiol 1995, 33:1278-1282. This meta-analysis suggests that neither endotoxaemia nor Gram-negative bacteraemia alone can predict outcome in patients with suspected intra-abdominal sepsis. In combination, however, the two identified a subpopulation with a substantially increased risk for mortality.
90. Friedmann G, Berlot G, Kahn RJ, Vincent JL: Combined measurements of blood lactate concentrations and gastric intramucosal pH in patients with severe sepsis. Crit Care Med 1995, 23:1184-1193.